GSK (LON:GSK) Insider Buys £28,215 in Stock

GSK plc (LON:GSK) insider Jonathan Symonds purchased 1,500 shares of GSK stock in a transaction dated Friday, September 18th. The stock was bought at an average cost of GBX 1,881 per share, with a total value of £28,215.

GSK Trading Down 0.5%

Shares of LON GSK opened at GBX 1,877 on Friday. The stock has a market capitalization of £75.21 billion, a P/E ratio of 15.93, a price-to-earnings-growth ratio of 1.24 and a beta of 0.29. The business has a fifty day moving average price of GBX 1,888.78 and a 200 day moving average price of GBX 1,949.39. GSK plc has a 1-year low of GBX 1,455 and a 1-year high of GBX 2,282. The company has a debt-to-equity ratio of 103.36, a current ratio of 0.82 and a quick ratio of 0.73.

GSK (LON:GSK) last issued its quarterly earnings results on Tuesday, July 28th. The company reported GBX 10.80 earnings per share (EPS) for the quarter. GSK had a return on equity of 28.35% and a net margin of 14.52%. Equities research analysts expect that GSK plc will post 175.980975 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a GBX 2,000 price target on shares of GSK in a research note on Tuesday, September 15th. Royal Bank Of Canada reissued a “sector perform” rating and set a GBX 1,975 target price on shares of GSK in a research report on Tuesday, September 8th. Jefferies Financial Group restated a “buy” rating and set a GBX 2,500 price target on shares of GSK in a research note on Wednesday, July 29th. Finally, Berenberg Bank raised their price target on shares of GSK from GBX 2,000 to GBX 2,200 and gave the stock a “hold” rating in a report on Tuesday, September 15th. Two investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, GSK has a consensus rating of “Hold” and a consensus price target of GBX 2,064.38.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.